Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Morand

Showing results (141-150 of 226) with videos related to

Pageof 23
Sort By:
Arthritis Research & Therapy|July 29, 2006
Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritisAngela Pakozdi, Mohammad A Amin, Christian S Haas, et al.
Immunology and Cell Biology|June 2, 2022
Investigating immunoregulatory effects of myeloid cell autophagy in acute and chronic inflammationMd Abul Hasnat, IanIan Cheang, Wendy Dankers, et al.
Rheumatology (Oxford, England)|February 6, 2021
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosusDaniel J Wallace, David A Isenberg, Eric F Morand, et al.
Development (Cambridge, England)|August 22, 2018
GILZ-dependent modulation of mTORC1 regulates spermatogonial maintenanceHue M La, Ai-Leen Chan, Julien M D Legrand, et al.
International Immunopharmacology|June 8, 2018
Formyl peptide receptor activation inhibits the expansion of effector T cells and synovial fibroblasts and attenuates joint injury in models of rheumatoid arthritisDragana Odobasic, Yuan Jia, Wenping Kao, et al.
Annals of the Rheumatic Diseases|February 13, 2025
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsEric F Morand, Ronald van Vollenhoven, Richard A Furie, et al.
ACR Open Rheumatology|September 15, 2023
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II StudiesMatthew Studham, Cristina Vazquez-Mateo, Eileen Samy, et al.
Modern Rheumatology|January 13, 2025
Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 studyYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Rheumatology (Oxford, England)|August 14, 2024
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosusKatie Liao, Ning Li, Julie Bonin, et al.
British Journal of Pharmacology|August 29, 2012
Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1(2-26)Chengxue Qin, Keith D Buxton, Salvatore Pepe, et al.
Pageof 23

Showing results (141-150 of 226) with videos related to

Sort By:
Pageof 23
Arthritis Research & Therapy|July 29, 2006
Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritisAngela Pakozdi, Mohammad A Amin, Christian S Haas, et al.
Immunology and Cell Biology|June 2, 2022
Investigating immunoregulatory effects of myeloid cell autophagy in acute and chronic inflammationMd Abul Hasnat, IanIan Cheang, Wendy Dankers, et al.
Rheumatology (Oxford, England)|February 6, 2021
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosusDaniel J Wallace, David A Isenberg, Eric F Morand, et al.
Development (Cambridge, England)|August 22, 2018
GILZ-dependent modulation of mTORC1 regulates spermatogonial maintenanceHue M La, Ai-Leen Chan, Julien M D Legrand, et al.
International Immunopharmacology|June 8, 2018
Formyl peptide receptor activation inhibits the expansion of effector T cells and synovial fibroblasts and attenuates joint injury in models of rheumatoid arthritisDragana Odobasic, Yuan Jia, Wenping Kao, et al.
Annals of the Rheumatic Diseases|February 13, 2025
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsEric F Morand, Ronald van Vollenhoven, Richard A Furie, et al.
ACR Open Rheumatology|September 15, 2023
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II StudiesMatthew Studham, Cristina Vazquez-Mateo, Eileen Samy, et al.
Modern Rheumatology|January 13, 2025
Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 studyYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Rheumatology (Oxford, England)|August 14, 2024
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosusKatie Liao, Ning Li, Julie Bonin, et al.
British Journal of Pharmacology|August 29, 2012
Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1(2-26)Chengxue Qin, Keith D Buxton, Salvatore Pepe, et al.
Pageof 23